Medicinal chemistry approaches to target the MNK-eIF4E axis in cancer

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Aberrant protein translation drives cancer progression.
• The eukaryotic initiation factor 4E (eIF4E) controls translation initiation.
• The MNK1/2-eIF4E axis is frequently dysregulated in various cancers.

Purpose of the Study:

• To review recent advancements in developing small molecule therapeutics targeting the MNK-eIF4E pathway.
• To explore diverse molecular strategies for targeting this axis in cancer treatment.
• To discuss the medicinal chemistry principles guiding the optimization and testing of these agents.

Main Methods:

• Literature review of recent research on MNK-eIF4E inhibitors.
• Analysis of small molecule inhibitors targeting different components of the MNK-eIF4E axis.
• Discussion of medicinal chemistry approaches for drug optimization.

Main Results:

• Several small molecules targeting MNK1/2 kinases and eIF4E have been developed.
• These inhibitors demonstrate potential in preclinical cancer models.
• Medicinal chemistry efforts are optimizing potency, selectivity, and pharmacokinetic properties.

Conclusions:

• The MNK-eIF4E axis represents a viable therapeutic target for cancer.
• Small molecule inhibitors targeting this pathway offer a promising avenue for novel cancer drug development.
• Continued research in medicinal chemistry is crucial for advancing these agents towards clinical application.